StockData
Becton Dickinson & Co logo

Becton Dickinson & Co (BDX) KPIs and segments

BDXNYSESurgical & Medical Instruments & ApparatusFiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 13/3018% above fair value
$216.47−1.56 (-0.72%)

Close on Nov 16, 2026Market cap $58.96BP/E 65.4Yield 1.92%

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Becton Dickinson · năm tài chính kết thúc September 30 (FY2026 ended September 30, 2026; Biosciences & Diagnostic Solutions spin-off completed February 9, 2026)

Nhìn nhanh KPI của Becton Dickinson: 58 chỉ số vận hành, trong đó có Consolidated Revenue Growth Bridge, New BD Continuing Operations — Organic Revenue và Remaining Performance Obligations (RPO), lấy từ 249 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Năm tài chính của Becton Dickinson kết thúc September 30 (FY2026 ended September 30, 2026; Biosciences & Diagnostic Solutions spin-off completed February 9, 2026) — Q4 FY26 = CQ3 2026 (quý dương lịch).

Periods

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q4 FY26
Q3 FY26
Q2 FY26
Q1 FY26
Q4 FY25
Q3 FY25
Q2 FY25
Q1 FY25
Q4 FY24
Q3 FY24
Q2 FY24
Q1 FY24
Medical($M)2
3,1542,9272,7602,6152,8372,5582,4492,230
U S($M)
1,9041,7431,6531,6151,6671,5081,4291,360
International($M)
1,2501,1841,1079991,1701,0501,020870
Medical Essentials($M)2
1,6751,6471,5951,6021,5731,586
U S($M)
994965938920929932
International($M)
681682658682643654
Interventional($M)2
1,4141,3571,3301,3681,3281,2641,2571,2601,2401,2921,188
U S($M)
957933914905898880861851844898802
International($M)
457423416462430384396409396395386
Connected Care($M)2
1,2241,1201,1311,1661,0681,073
U S($M)
926840857885817818
International($M)
297280275281251255
Life Sciences($M)2
7661,3691,2541,2478361,3391,2601,3041,288
International($M)
466757714673470742714724701
U S($M)
300611539574365598546579587
BioPharma Systems($M)
670590429629575418
U S($M)
3,0812,9173,1594,4182,8822,7763,0803,1172,8912,9062,749
International($M)
1,9021,7972,0933,8831,8441,7042,0892,3202,0982,1391,957
Medical Essentials($M)
617574569612617607
Interventional($M)
565579561579549565561
Connected Care($M)
395347352417353336
BioPharma Systems($M)
259225140239224141
Life Sciences($M)
159240
Interventional($M)
912928885907882863853
Medical Essentials($M)
849812795825830816
Connected Care($M)
696630630668590590
Life Sciences($M)
373451
BioPharma Systems($M)
308274186287269186
Medical($M)
880550492792753662535
Life Sciences($M)
391377383421387415372
Interventional($M)
376392387376365388291
Life Sciences($M)
-6-9
Connected Care($M)
-12-16
Interventional($M)
-17-23
BioPharma Systems($M)
-29-21
Medical Essentials($M)
-40-35
Consolidated Revenue Growth Bridge — Volume & Mix YoY (%)(%)3
4.1%2.4%0.3%3.5%1.0%3.5%4.9%5.0%0.5%
Consolidated Revenue Growth Bridge — Pricing YoY (%)(%)
0.3%0.2%0.1%-0.5%-0.1%0.4%0.3%0.6%2.0%
Consolidated Revenue Growth Bridge — Foreign Currency Translation YoY (%)(%)
1.0%2.6%1.2%0.5%-1.5%0.2%-0.6%-0.1%1.0%
Consolidated Revenue Growth Bridge — Total Revenue Change YoY (%)(%)
5.4%5.2%1.6%10.4%4.5%9.8%2.3%4.6%2.6%
New BD Continuing Operations — Organic Revenue ($M)($M)4
4,8354,4484,2234,0624,5594,2644,2003,864
New BD Organic Revenue — FX-Neutral Growth YoY (%)(%)
4.9%4.0%1.9%4.9%
New BD Organic Revenue — Reported Growth YoY (%)(%)
6.1%4.3%0.6%5.1%
New BD Organic Revenue — Foreign Currency Impact ($M)($M)
5415-576
New BD Continuing Operations — Reported Revenue ($M)($M)3
5,0054,7264,4804,3334,5594,2644,2003,864
New BD Reported Revenue — FX-Neutral Growth YoY (%)(%)
8.5%10.4%8.1%11.9%
New BD Reported Revenue — Reported Growth YoY (%)(%)
9.8%10.8%6.7%12.1%
Inorganic M&A Revenue Contribution (Advanced Patient Monitoring, $M)($M)
17027825727174
Remaining Performance Obligations (RPO) — Service & Pending Equipment Installations ($M)($M)3
2,3002,3002,5002,8002,5002,4002,3002,3002,3002,3002,200
Remaining Performance Obligations (RPO) — Minimum Consumable Commitments ($M)($M)
2,0002,0002,4002,3002,3002,2002,0002,1002,1002,1002,200
Customer Contract Liabilities / Unearned Service Revenue ($M)($M)
334337457336492495502482449440419
Customer Rebate Accrual Liabilities ($M)($M)
860880933817825822813749646593597
Developed Markets Revenue ($M)($M)3
4,5754,3654,1214,5354,3664,1133,9334,4393,990
Developed Markets — FX-Neutral Revenue Growth YoY (%)(%)
5.4%5.5%2.5%1.1%1.6%
Developed Markets — Reported Revenue Growth YoY (%)(%)
4.8%6.1%4.8%2.2%2.7%
Developed Markets — Foreign Currency Impact ($M)($M)
-2527904740
Emerging Markets Revenue ($M)($M)4
699618592718639613547729716
Emerging Markets — FX-Neutral Revenue Growth YoY (%)(%)
7.2%-2.6%3.5%-3.7%1.2%
Emerging Markets — Reported Revenue Growth YoY (%)(%)
9.4%0.8%8.3%-1.6%2.5%
Emerging Markets — Foreign Currency Impact ($M)($M)
142126169
Greater China Revenue ($M)($M)3
228223209255242236222295300
Greater China — FX-Neutral Revenue Growth YoY (%)(%)
-9.5%-10.0%-9.8%-13.9%-5.3%
Greater China — Reported Revenue Growth YoY (%)(%)
-5.8%-5.6%-6.2%-13.5%-6.8%
Greater China — Foreign Currency Impact ($M)($M)
91081-5
Medical Essentials Segment — Worldwide Revenue ($M)($M)7
1,7861,6751,6471,5951,6861,6021,5731,5861,6091,5901,5651,498
Medical Essentials Segment — FX-Neutral Revenue Growth YoY (%)(%)
5.9%3.2%1.7%-0.6%3.6%0.7%2.4%5.8%
Medical Essentials Segment — Reported Revenue Growth YoY (%)(%)
5.9%4.5%4.7%0.6%4.8%0.8%0.5%5.8%
Medical Essentials Segment — Foreign Currency Translation Impact ($M)($M)
214719191-301
Medical Essentials Segment — U.S. Revenue ($M)($M)1
1,048994965938988920929932933909898873
Medical Essentials Segment — U.S. Revenue Growth YoY (%)(%)
6.0%8.0%3.9%0.6%5.9%1.3%3.5%6.8%
Medical Essentials Segment — International Revenue ($M)($M)2
738681682658697682643654676681667626
Medical Essentials Segment — International FX-Neutral Growth YoY (%)(%)
5.8%-3.2%-1.4%-2.3%0.4%-0.1%0.9%4.3%
Medical Essentials Segment — International Reported Growth YoY (%)(%)
5.8%-0.1%6.0%0.6%3.2%0.1%-3.5%4.4%
Medication Delivery Solutions (MDS) — Worldwide Revenue ($M)($M)5
1,2561,1641,1631,1281,2021,1321,1171,1241,1471,1231,1071,052
Medication Delivery Solutions (MDS) — FX-Neutral Revenue Growth YoY (%)(%)
4.5%1.6%1.4%-0.7%3.8%0.7%2.8%6.8%5.2%3.9%3.5%0.2%
Medication Delivery Solutions (MDS) — Reported Revenue Growth YoY (%)(%)
4.5%2.8%4.1%0.3%4.8%0.8%0.9%6.9%4.4%3.4%3.5%1.2%
Medication Delivery Solutions (MDS) — Foreign Currency Translation Impact ($M)($M)
133112121-201-8-610
Medication Delivery Solutions (MDS) — U.S. Revenue ($M)($M)1
764720712693728680687694689670662639
Medication Delivery Solutions (MDS) — U.S. Revenue Growth YoY (%)(%)
4.9%5.9%3.7%-0.2%5.7%1.4%3.7%8.6%5.0%6.8%7.6%3.1%
Medication Delivery Solutions (MDS) — International Revenue ($M)($M)2
493444451435474452430430458453445413
Medication Delivery Solutions (MDS) — International FX-Neutral Growth YoY (%)(%)
3.9%-4.7%-2.2%-1.7%0.9%-0.3%1.3%4.1%5.5%-2.0%-4.0%
Medication Delivery Solutions (MDS) — International Reported Growth YoY (%)(%)
3.9%-1.8%4.9%1.2%3.5%-0.1%-3.3%4.3%3.6%-1.3%-2.1%-1.6%
Specimen Management (SM) — Worldwide Revenue ($M)($M)5
529511484468483470456462462467458447
Specimen Management (SM) — FX-Neutral Revenue Growth YoY (%)(%)
9.4%7.0%2.5%-0.3%3.3%0.6%1.4%3.3%
Specimen Management (SM) — Reported Revenue Growth YoY (%)(%)
9.5%8.7%6.2%1.3%4.7%0.7%-0.6%3.3%
Specimen Management (SM) — Foreign Currency Translation Impact ($M)($M)
817771-9
Specimen Management (SM) — U.S. Revenue ($M)($M)1
284274253245260240242238244239236234
Specimen Management (SM) — U.S. Revenue Growth YoY (%)(%)
9.2%14.0%4.5%2.9%6.6%0.8%2.7%2.0%
Specimen Management (SM) — International Revenue ($M)($M)2
245237231222223230213223218228222213
Specimen Management (SM) — International FX-Neutral Growth YoY (%)(%)
9.7%-0.2%0.3%-3.7%-0.5%0.3%0.1%4.7%
Specimen Management (SM) — International Reported Growth YoY (%)(%)
9.9%3.1%8.1%-0.4%2.6%0.7%-4.1%4.8%
Connected Care Segment — Worldwide Revenue ($M)($M)8
1,2691,2241,1201,1311,2501,1661,0681,0731,013840772747
Connected Care Segment — FX-Neutral Revenue Growth YoY (%)(%)
2.1%4.4%3.2%4.7%22.5%38.2%39.7%43.3%
Connected Care Segment — Reported Revenue Growth YoY (%)(%)
1.6%4.9%4.9%5.5%23.4%38.8%38.4%43.7%
Connected Care Segment — Foreign Currency Translation Impact ($M)($M)
-76188105-103
Connected Care Segment — U.S. Revenue ($M)($M)1
940926840857949885817818791680609594
Connected Care Segment — U.S. Revenue Growth YoY (%)(%)
-1.0%4.6%2.9%4.8%20.0%30.2%34.1%37.7%
Connected Care Segment — International Revenue ($M)($M)2
330297280275301281251255222160162153
Connected Care Segment — International FX-Neutral Growth YoY (%)(%)
11.9%3.9%4.5%4.7%31.3%72.1%60.7%65.3%
Connected Care Segment — International Reported Growth YoY (%)(%)
9.6%5.9%11.6%7.7%35.7%75.1%54.6%67.0%
Connected Care — Organic Revenue Excl. APM Acquisition ($M)($M)2
1,0798888118011,013840772747
Connected Care Organic Revenue — FX-Neutral Growth YoY (%)(%)
5.9%5.3%5.9%7.1%
Connected Care Organic Revenue — Reported Growth YoY (%)(%)
6.6%5.7%5.1%7.3%
Medication Management Solutions (MMS) — Worldwide Revenue ($M)($M)5
952915829835974888811801939840772747
Medication Management Solutions (MMS) — FX-Neutral Revenue Growth YoY (%)(%)
-2.2%2.3%0.4%3.4%3.1%5.3%5.9%7.1%18.0%11.6%6.5%5.0%
Medication Management Solutions (MMS) — Reported Revenue Growth YoY (%)(%)
-2.3%3.0%2.2%4.1%3.8%5.7%5.1%7.3%17.9%11.5%6.7%5.7%
Medication Management Solutions (MMS) — Foreign Currency Translation Impact ($M)($M)
-1614663-62-1-115
Medication Management Solutions (MMS) — U.S. Revenue ($M)($M)1
736737660678780709662659744680609594
Medication Management Solutions (MMS) — U.S. Revenue Growth YoY (%)(%)
-5.6%3.9%-0.2%2.9%4.9%4.3%8.6%11.0%23.6%15.9%10.7%5.3%
Medication Management Solutions (MMS) — International Revenue ($M)($M)2
216178168156194179149142195160162153
Medication Management Solutions (MMS) — International FX-Neutral Growth YoY (%)(%)
11.8%-4.0%3.3%5.5%-3.8%9.6%-4.5%-8.2%0.6%-3.4%-7.1%3.5%
Medication Management Solutions (MMS) — International Reported Growth YoY (%)(%)
11.4%-0.4%12.7%9.7%-0.4%11.4%-8.2%-6.9%0.3%-4.0%-6.3%7.3%
Advanced Patient Monitoring (APM) — Worldwide Revenue ($M)($M)5
31730929229727627825727174000
Advanced Patient Monitoring (APM) — FX-Neutral Revenue Growth YoY (%)(%)
17.3%11.2%12.0%8.8%
Advanced Patient Monitoring (APM) — Reported Revenue Growth YoY (%)(%)
15.0%10.9%13.6%9.4%
Advanced Patient Monitoring (APM) — Foreign Currency Translation Impact ($M)($M)
-6-14232-41
Advanced Patient Monitoring (APM) — U.S. Revenue ($M)($M)1
20318918017816917615515947000
Advanced Patient Monitoring (APM) — U.S. Revenue Growth YoY (%)(%)
20.5%7.4%15.9%12.4%
Advanced Patient Monitoring (APM) — International Revenue ($M)($M)2
11412011211910710210211327000
Advanced Patient Monitoring (APM) — International FX-Neutral Growth YoY (%)(%)
12.2%17.8%6.2%3.7%
Advanced Patient Monitoring (APM) — International Reported Growth YoY (%)(%)
6.4%17.1%10.0%5.1%
BioPharma Systems (formerly Pharmaceutical Systems) — Worldwide Revenue ($M)($M)5
748670590429702629575418677594570431
BioPharma Systems (formerly Pharmaceutical Systems) — FX-Neutral Revenue Growth YoY (%)(%)
7.0%5.2%-1.8%1.0%1.4%4.8%2.2%-3.2%3.0%0.9%0.3%3.4%
BioPharma Systems (formerly Pharmaceutical Systems) — Reported Revenue Growth YoY (%)(%)
6.5%6.6%2.5%2.7%3.7%5.8%0.9%-3.2%2.7%0.1%0.6%5.4%
BioPharma Systems (formerly Pharmaceutical Systems) — Foreign Currency Translation Impact ($M)($M)
-49257166-7-2-418
BioPharma Systems (formerly Pharmaceutical Systems) — U.S. Revenue ($M)($M)1
238204178150228178149104187158157127
BioPharma Systems (formerly Pharmaceutical Systems) — U.S. Revenue Growth YoY (%)(%)
4.7%14.2%19.4%45.0%21.5%13.2%-5.1%-18.5%-0.4%-15.4%-9.0%6.9%
BioPharma Systems (formerly Pharmaceutical Systems) — International Revenue ($M)($M)2
509467411279475451426314490437413304
BioPharma Systems (formerly Pharmaceutical Systems) — International FX-Neutral Growth YoY (%)(%)
8.1%1.6%-9.2%-13.5%-6.3%1.7%5.0%3.2%4.4%8.3%4.5%2.0%
BioPharma Systems (formerly Pharmaceutical Systems) — International Reported Growth YoY (%)(%)
7.3%3.6%-3.4%-11.2%-3.1%3.1%3.2%3.2%4.0%7.2%4.8%4.8%
Interventional Segment — Worldwide Revenue ($M)($M)8
1,4721,4141,3571,3301,3671,3281,2641,2571,2601,2401,2921,188
Interventional Segment — FX-Neutral Revenue Growth YoY (%)(%)
7.6%5.5%5.3%5.1%7.5%6.8%-1.1%5.5%5.4%2.6%9.5%4.7%
Interventional Segment — Reported Revenue Growth YoY (%)(%)
7.6%6.4%7.3%5.8%8.5%7.2%-2.2%5.8%4.7%1.8%9.0%5.2%
Interventional Segment — Foreign Currency Translation Impact ($M)($M)
122610134-144-8-10-66
Interventional Segment — U.S. Revenue ($M)($M)1
978957933914905898880861851844898802
Interventional Segment — U.S. Revenue Growth YoY (%)(%)
8.0%6.6%6.0%6.2%6.4%6.5%-1.9%7.4%3.0%2.1%10.4%2.5%
Interventional Segment — International Revenue ($M)($M)2
494457423416462430384396409396395386
Interventional Segment — International FX-Neutral Growth YoY (%)(%)
6.9%3.3%3.6%2.6%9.8%7.6%0.8%1.5%10.5%3.7%7.3%9.6%
Interventional Segment — International Reported Growth YoY (%)(%)
6.8%6.2%10.4%5.1%13.0%8.6%-2.8%2.4%8.5%1.0%5.9%11.2%
Peripheral Intervention (PI) — Worldwide Revenue ($M)($M)5
577552515485530512481473502488489454
Peripheral Intervention (PI) — FX-Neutral Revenue Growth YoY (%)(%)
8.3%6.1%4.0%1.4%4.3%4.5%0.1%3.8%4.9%2.6%5.0%4.1%
Peripheral Intervention (PI) — Reported Revenue Growth YoY (%)(%)
8.8%7.8%7.1%2.6%5.6%4.8%-1.5%4.1%4.1%1.5%4.3%4.8%
Peripheral Intervention (PI) — Foreign Currency Translation Impact ($M)($M)
2915671-81-4-5-33
Peripheral Intervention (PI) — U.S. Revenue ($M)($M)1
297294279265275271269253267263264234
Peripheral Intervention (PI) — U.S. Revenue Growth YoY (%)(%)
8.3%8.4%3.9%5.1%2.9%2.9%1.9%7.8%-0.4%2.8%3.3%-0.7%
Peripheral Intervention (PI) — International Revenue ($M)($M)2
280258236220256241212220235225225220
Peripheral Intervention (PI) — International FX-Neutral Growth YoY (%)(%)
8.4%3.5%4.1%-2.8%5.8%6.4%-1.9%-0.4%11.5%2.4%7.0%9.8%
Peripheral Intervention (PI) — International Reported Growth YoY (%)(%)
9.3%7.2%11.1%-0.2%8.7%7.0%-5.5%0.2%9.7%5.6%11.4%
Urology and Critical Care (UCC) — Worldwide Revenue ($M)($M)5
473440430427437422400389390375424365
Urology and Critical Care (UCC) — FX-Neutral Revenue Growth YoY (%)(%)
8.7%4.2%6.5%9.5%11.5%12.1%-5.1%6.3%10.3%8.3%26.7%9.3%
Urology and Critical Care (UCC) — Reported Revenue Growth YoY (%)(%)
8.2%4.2%7.5%9.8%12.2%12.5%-5.8%6.6%9.7%7.4%26.1%9.5%
Urology and Critical Care (UCC) — Foreign Currency Translation Impact ($M)($M)
-24132-31-2-3-21
Urology and Critical Care (UCC) — U.S. Revenue ($M)($M)1
382357351339341334323306306297347287
Urology and Critical Care (UCC) — U.S. Revenue Growth YoY (%)(%)
11.9%7.1%8.6%10.9%11.6%12.4%-6.8%6.6%9.4%9.1%31.9%10.8%
Urology and Critical Care (UCC) — International Revenue ($M)($M)2
928279889788778384787878
Urology and Critical Care (UCC) — International FX-Neutral Growth YoY (%)(%)
-2.7%-6.9%-2.3%4.0%11.1%10.8%2.6%5.4%13.8%5.6%8.2%4.0%
Urology and Critical Care (UCC) — International Reported Growth YoY (%)(%)
-5.0%-6.7%3.0%5.5%14.7%12.7%-1.3%6.8%11.0%1.4%5.4%5.0%
Surgery (SURG) — Worldwide Revenue ($M)($M)5
422422411418400395383395368376379369
Surgery (SURG) — FX-Neutral Revenue Growth YoY (%)(%)
5.5%6.2%5.5%5.1%7.6%4.6%1.9%6.8%1.1%-2.5%-0.3%1.2%
Surgery (SURG) — Reported Revenue Growth YoY (%)(%)
5.5%7.0%7.4%5.9%8.5%4.9%1.0%7.0%0.7%-3.0%-0.5%1.7%
Surgery (SURG) — Foreign Currency Translation Impact ($M)($M)
37331-31-2-2-12
Surgery (SURG) — U.S. Revenue ($M)($M)1
299306303310290294289303279283287280
Surgery (SURG) — U.S. Revenue Growth YoY (%)(%)
3.2%4.3%4.9%2.3%4.0%3.6%0.5%8.0%-0.1%-4.8%-2.6%-2.3%
Surgery (SURG) — International Revenue ($M)($M)2
122116109108110101949289939288
Surgery (SURG) — International FX-Neutral Growth YoY (%)(%)
11.7%11.7%7.3%14.3%18.9%7.7%6.1%2.9%5.0%5.1%7.5%14.4%
Surgery (SURG) — International Reported Growth YoY (%)(%)
11.6%15.0%14.9%17.6%22.6%9.0%2.5%4.1%3.2%3.1%6.9%17.1%
Medical Essentials — Segment Operating Income ($M)($M)7
617574569612617607
Medical Essentials — Segment Operating Margin (% of Segment Revenue)(%)
36.8%34.8%35.6%38.2%39.3%38.3%
Medical Essentials — Segment Cost of Products Sold ($M)($M)1
826835800777743770
Medical Essentials — Segment Cost of Products Sold (% of Revenue)(%)
49.3%50.7%50.1%48.5%47.0%48.5%
Medical Essentials — Segment Selling & Administrative Expense ($M)($M)1
183185180169164165
Medical Essentials — Segment Selling & Administrative (% of Revenue)(%)
10.9%11.2%11.3%10.5%10.4%10.4%
Medical Essentials — Segment Research & Development Expense ($M)($M)1
495347444844
Medical Essentials — Segment R&D Expense (% of Revenue)(%)
2.9%3.2%2.9%2.8%3.1%2.8%
Medical Essentials — Segment Other Operating Expense ($M)($M)1
000000
Medical Essentials — Segment Depreciation & Amortization ($M)($M)
138147141145136135
Medical Essentials — Segment Goodwill Balance ($M)($M)
7,0207,0107,0157,011
Connected Care — Segment Operating Income ($M)($M)7
395347352417353336
Connected Care — Segment Operating Margin (% of Segment Revenue)(%)
32.3%31.0%31.1%35.8%33.0%31.3%
Connected Care — Segment Cost of Products Sold ($M)($M)1
528490501498478483
Connected Care — Segment Cost of Products Sold (% of Revenue)(%)
43.2%43.7%44.3%42.7%44.8%45.0%
Connected Care — Segment Selling & Administrative Expense ($M)($M)1
195190191172161168
Connected Care — Segment Selling & Administrative (% of Revenue)(%)
15.9%17.0%16.9%14.8%15.1%15.7%
Connected Care — Segment Research & Development Expense ($M)($M)1
1029085747480
Connected Care — Segment R&D Expense (% of Revenue)(%)
8.3%8.1%7.5%6.4%6.9%7.4%
Connected Care — Segment Other Operating Expense ($M)($M)1
-4-3-3-5-2-6
Connected Care — Segment Depreciation & Amortization ($M)($M)
199194194198199194
Connected Care — Segment Goodwill Balance ($M)($M)
6,0936,0956,0936,093
BioPharma Systems — Segment Operating Income ($M)($M)7
259225140239224141
BioPharma Systems — Segment Operating Margin (% of Segment Revenue)(%)
38.6%38.1%32.6%38.1%38.9%33.7%
BioPharma Systems — Segment Cost of Products Sold ($M)($M)1
362316243342306232
BioPharma Systems — Segment Cost of Products Sold (% of Revenue)(%)
54.0%53.6%56.6%54.4%53.2%55.4%
BioPharma Systems — Segment Selling & Administrative Expense ($M)($M)1
313229292829
BioPharma Systems — Segment Selling & Administrative (% of Revenue)(%)
4.7%5.4%6.6%4.6%4.8%6.8%
BioPharma Systems — Segment Research & Development Expense ($M)($M)1
181718181817
BioPharma Systems — Segment R&D Expense (% of Revenue)(%)
2.7%2.8%4.1%2.9%3.1%4.1%
BioPharma Systems — Segment Other Operating Expense ($M)($M)1
000000
BioPharma Systems — Segment Depreciation & Amortization ($M)($M)
422734293231
BioPharma Systems — Segment Goodwill Balance ($M)($M)
97969696
Interventional — Segment Operating Income ($M)($M)7
565579561579549565561
Interventional — Segment Operating Margin (% of Segment Revenue)(%)
39.9%42.7%42.1%41.3%44.7%44.6%
Interventional — Segment Cost of Products Sold ($M)($M)1
502429445461446401404
Interventional — Segment Cost of Products Sold (% of Revenue)(%)
35.5%31.6%33.5%33.6%31.7%32.1%
Interventional — Segment Selling & Administrative Expense ($M)($M)1
277277262254271236237
Interventional — Segment Selling & Administrative (% of Revenue)(%)
19.6%20.4%19.7%20.4%18.6%18.9%
Interventional — Segment Research & Development Expense ($M)($M)1
70726373636356
Interventional — Segment R&D Expense (% of Revenue)(%)
4.9%5.3%4.7%4.7%5.0%4.4%
Interventional — Segment Other Operating Expense ($M)($M)1
0000000
Interventional — Segment Depreciation & Amortization ($M)($M)
182192197196200198200
Interventional — Segment Goodwill Balance ($M)($M)
12,73412,75512,76712,76412,75612,68712,66312,72912,68112,69212,708
BD Medical Segment (Legacy through FY2025) — Segment Operating Income ($M)1
BD Life Sciences Segment (Legacy through FY2026Q1) — Segment Operating Income ($M)1
Unallocated Corporate Expenses & Shared Functions ($M)($M)
616595690754584636682
Adjusted Gross Profit — Non-GAAP ($M)($M)4
2,9942,7052,5792,4362,7512,6122,4922,387
Adjusted Gross Margin (% of Revenues)(%)
56.8%54.3%54.7%53.4%55.0%55.3%55.6%54.8%
GAAP Gross Margin (% of Revenues)(%)
51.1%46.4%45.7%45.9%47.3%47.3%41.5%43.3%
Reported GAAP Gross Profit — Continuing Operations ($M)($M)
2,0522,3662,2351,8611,797
Non-GAAP Adjustment: Purchase Accounting Amortization & Step-Up ($M)($M)
346384383377544562
Adjusted Operating Income — Non-GAAP ($M)($M)5
1,5091,2401,1429781,2921,2371,1331,005
Adjusted Operating Margin (% of Revenues)(%)
28.6%24.9%24.2%21.2%25.8%26.2%25.3%23.6%
GAAP Operating Margin (% of Revenues)(%)
19.6%13.3%2.0%10.5%10.7%15.6%8.6%8.8%
Reported GAAP Operating Income — Continuing Operations ($M)($M)
468536740383282
Adjusted SSG&A Expense — Non-GAAP ($M)($M)2
1,2621,2321,2281,3871,1951,1431,1261,308
Adjusted SSG&A Expense (% of Revenues)(%)
23.9%24.7%26.0%26.4%23.9%24.2%25.1%25.3%
GAAP SSG&A Expense (% of Revenues)(%)
23.9%25.3%25.7%26.5%24.1%24.6%24.9%25.5%
Adjusted R&D Expense — Non-GAAP ($M)($M)2
243254246303261228230305
Adjusted R&D Expense (% of Revenues)(%)
4.6%5.1%5.2%5.8%5.2%4.8%5.1%5.9%
GAAP R&D Expense (% of Revenues)(%)
4.7%5.2%5.3%5.8%5.3%4.9%5.2%6.6%
Adjusted Net Income from Continuing Operations — Non-GAAP ($M)($M)6
1,136888816716937884804808
Adjusted Net Margin (% of Revenues)(%)
21.5%17.8%17.3%15.8%18.7%18.7%17.9%19.3%
GAAP Net Margin (% of Revenues)(%)
13.1%9.1%-0.8%7.3%6.9%9.5%3.5%5.9%
Adjusted Income Tax Provision — Non-GAAP ($M)($M)
23120317311117720117374
Adjusted Effective Tax Rate (%)(%)
16.9%18.6%17.5%11.8%15.9%18.5%17.7%6.9%
GAAP Effective Tax Rate (%)(%)
23.2%18.5%193.1%2.8%1.9%20.8%21.5%0.9%
Adjusted Diluted EPS from Continuing Operations — Non-GAAP ($)($)1
4.153.232.902.503.263.082.792.783.8112.2112.2112.21
Reported GAAP Diluted EPS from Continuing Operations ($)($)
2.521.091.201.570.550.50
LTM Adjusted EBITDA — Continuing Operations ($M)($M)2
5,8425,6095,6095,561
Net Debt (Total Debt Less Cash & Short-Term Investments, $M)($M)
15,61116,09916,46314,928
Net Leverage Ratio (Net Debt / LTM Adjusted EBITDA, x)(×)
2.702.902.902.70
Inventories by Production Stage — Total ($M)($M)3
3,1913,3163,3574,0853,1493,9493,7233,8603,8433,2553,2293,304
Finished Products Inventory ($M)($M)
2,1222,1612,6502,0712,5182,3442,5022,5972,0872,0762,160
Work in Process Inventory ($M)($M)
401396495354512487453443406376368
Materials & Supplies (Raw Materials) Inventory ($M)($M)
793801940724920892904803763777776
Property, Plant & Equipment, Gross ($M)($M)2
13,60413,55215,23713,65614,85414,40914,15614,37813,92213,92513,899
Accumulated Depreciation & Amortization on PP&E ($M)($M)
7,5217,4708,2657,2728,0367,7637,5547,5577,4047,3347,253
Property, Plant & Equipment, Net ($M)($M)
6,1916,0836,0826,9726,3836,8186,6466,6026,8216,5186,5916,647
Acquired Intangible Assets (Excl. Goodwill), Gross ($M)($M)8
21,32321,28922,67321,57522,63622,54422,48622,52521,12621,11921,119
Restructuring Liability Reserve Balance — Total ($M)($M)4
7379765876745360427081
Restructuring Reserve — Employee Termination & Severance ($M)($M)
3131473163514758416980
Restructuring Reserve — Other Restructuring & Plant Exit ($M)($M)
42482927132362111
Restructuring Accrual Charges Recorded ($M)($M)
484827588586366125959869
Restructuring Cash Payments Settled ($M)($M)
3736587354396585767965
Share Repurchases — Total Common Shares Repurchased (millions)(M)2
-3.219.321.310.622.642.12
Cash Paid for Common Share Repurchases ($M)($M)
02,00025025000750000500
Remaining Share Repurchase Authorization (million shares)(M)
8.3011.5111213134
Share-Based Compensation Expense — Total ($M)($M)
5573915455599050546083
Product Liability & Legal Matters Accrual Reserve Balance ($M)($M)5
1,6001,7001,7001,8001,9001,7001,7001,800
BD Pyxis / Alaris Product Remediation Liability Balance ($M)($M)
6883981141245028
Hernia Repair Mesh Product Liability Pending Claims (count)
7,0906,9956,9056,9056,8456,7906,6706,61038,80037,33035,935
Implantable Port Product Liability Pending Claims (count)
3,8503,2502,7652,380
Ethylene Oxide (EtO) Sterilization Pending Lawsuits (count)
435430420390390360235235
Ethylene Oxide (EtO) Pending Plaintiffs (count)
445440430400400375350350
Diagnostic Solutions Organizational Unit (Legacy through FY2026Q1) — Worldwide Revenue ($M)($M)5
439498425440474481429468467
Biosciences Organizational Unit (Legacy through FY2026Q1) — Worldwide Revenue ($M)($M)5
327387358352361397363377375
Discontinued Operations (BDS Spin-Off) — Revenues Reported by BD ($M)1
FDA 510(k) Premarket Notifications Cleared — BD & C.R. Bard1
465499761246
FDA 510(k) Premarket Notifications Cleared — U.S. MedTech Industry Total
855923756806797886736856767793713877
FDA Premarket Approvals (PMA & Supplements) — BD & C.R. Bard1
692243540224
FDA Premarket Approvals (PMA & Supplements) — U.S. MedTech Industry Total
565608567525585588524683538550459656
FDA openFDA Device Recall Records — BD & C.R. Bard1
1151851122161346
FDA Device Enforcement Reports — BD & C.R. Bard
1151815171843326
FDA MAUDE Adverse Event Reports — BD & C.R. Bard Total4
4,0443,5763,5704,88511,4094,3223,9003,9633,2023,2743,5334,413
U.S. PPI: Surgical & Medical Instrument Manufacturing (Index)1
Interventional — Segment Revenue ($M, DB)($M)1
1,4721,4141,3571,3301,3671,3281,2641,2571,2601,2401,2921,188
United States — Consolidated Revenue ($M, DB)($M)1
3,0812,9173,1593,4223,1813,1083,0803,1172,8912,9062,749
Consolidated Revenues ($M, DB)($M)16
5,2744,9834,7144,4865,0054,7264,4804,3335,4374,9905,0454,706
Total Assets ($M, DB)($M)10
50,79150,73150,83254,84155,32554,90254,46754,66557,28655,58254,15752,274
Operating Cash Flow — Continuing Operations ($M, DB)($M)5
7766716571,8521,089-2046931,1781,297514855

26 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Core Operational & Organizational Unit KPIs (Groups 1–2): Consolidated MD&A revenue growth decomposition into Volume/Mix (%), Pricing (%), and Foreign Currency (%); New BD organic vs. inorganic M&A revenue bridges; Remaining Performance Obligations (RPO) split between equipment/service installations ($2,756M at Q3 FY26) and minimum consumable commitments ($2,914M at Q3 FY26); customer contract & rebate liabilities; Developed Markets, Emerging Markets, and China revenues; and all 8 active organizational units across Worldwide, U.S., and International markets.
  • FY2026 Segment Reorganization & Life Sciences Spin-Off (Groups 2, 3 & 6): Effective October 1, 2025 (FY2026), BD reorganized its businesses into 4 continuing reportable segments — Medical Essentials (MDS, Specimen Management), Connected Care (MMS, Advanced Patient Monitoring), BioPharma Systems, and Interventional (PI, UCC, Surgery) — and on February 9, 2026 completed the spin-off and Reverse Morris Trust combination of its Biosciences & Diagnostic Solutions (BDS) business with Waters Corporation (receiving a $4,000M cash distribution). Standalone carve-out financials and operational metrics of the BDS Business (Product vs. Service revenue, Placed Instruments, RPO, Rebates, and DS/BS segment P&Ls) are tracked in Group 6 alongside legacy Diagnostic Solutions, Biosciences, and Diabetes Care (embecta) unit series.
  • Consolidated − Standalone Assessment (Step 3 & Step 4): Becton, Dickinson and Company files consolidated U.S. GAAP financial statements in Form 10-K/10-Q without parent-only Schedule I financial statements (restricted net assets of subsidiaries do not exceed 25% of consolidated net assets). Instead of parent subtraction, the separated BDS Business (SpinCo) is tracked directly from its audited carve-out financial statements (Form 8-K Exhibit 99.2 & Form 10-Q Exhibit 99.1) in Group 6, and UK operating subsidiaries Becton, Dickinson U.K. Limited (Co. 00852702) and Bard Limited (Co. 00939600) are tracked in Group 7.
  • Period Splitting & Strict Formula Compliance (Step 4): Only YTD subtraction ('quarter = year-to-date − previous year-to-date' and 'Q4 = full year − nine months') is used where SEC filings report cumulative year-to-date cash flows, segment footnotes, or full-year totals. Zero self-computed ratios, margins, YoY rates, or sums exist anywhere in output/kpis.json.

Không hiện vì thiếu các kỳ gần đây (24)

  • Consumables Share of Total Revenue ('over 90% of total revenue' in DEF 14A & Waters Transaction Deck) — Disclosed only as a lower bound ('>90%'); excluded per Step 5 bound rule.
  • Customer Service Levels ('over 90%' / 'above 90%' in Q2–Q4 FY2026 Earnings Presentations & Transcripts) — Disclosed only as a lower bound ('>90%'); excluded per Step 5 bound rule.
  • BD Excellence Annual Kaizen Events ('over 2,000 Kaizens' / 'more than 2,000 Kaizen events' in FY2026 Transcripts) — Disclosed only as a lower bound ('>2,000'); excluded per Step 5 bound rule.
  • BD Excellence Plant Gross Productivity Improvement ('over 8%' in FY2025 Annual Report & DEF 14A; '~8%' in FY2026 Transcripts) — Disclosed as a bound in FY2025 ('over 8%') and approximate figure in FY2026; excluded per Step 5.
  • GLP-1 & Biosimilar Drug Delivery Signed Customer Agreements ('over 80 deals' in Q2 FY2026; 'nearly 100 deals' in Q4 FY2026 Transcript) — Disclosed only as bounds ('over 80', 'nearly 100'); excluded per Step 5.
  • Annual New Product Launches ('over 25 new product launches' in FY2025 DEF 14A & '100+ new product launches by FY2025') — Disclosed only with bound qualifiers ('over 25', '100+'); excluded per Step 5.
  • U.S. & Puerto Rico Supplier Diversity Spend ($508M diverse-owned / 12% share, $809M small-business / 19% share in FY2022 ID&E Report; '$1.2+ billion' in FY2023 ESG Report) — Point figures disclosed only for a single year (FY2022) and as a bound ('$1.2+ billion') in FY2023 (<2 consecutive point years).
  • Global Manufacturing Network Optimization Plant Count ('a little over 90 plants' in FY2022 to 'under 50 global sites' in FY2026 Q1/Q2 Transcripts, with 'over 20 plant closures' and 'a little over 20 plants going to Waters') — Disclosed only as bounds in earnings call commentary; exact Item 2 total facility count (379–431 sites) and square footage (27.0M–32.2M sq. ft.) are tracked in Group 7.
  • Alaris Infusion System Category Market Share (~60% share in Q1 FY2026 Transcript; '>250 bps' FY2026 share gain in Q4 FY2026 Transcript; '85%' Pyxis Pro competitive conversions in Q1 FY2026) — Single-period point disclosures or bounds (<3 consecutive quarters); excluded per Step 5.
  • Segment Expense Structure, Operating Margins & Capital Allocation (ASU 2023-07) › Medical Essentials — Segment Operating Income ($M) › Medical Essentials — Segment Capital Expenditures ($M)
  • Segment Expense Structure, Operating Margins & Capital Allocation (ASU 2023-07) › Connected Care — Segment Operating Income ($M) › Connected Care — Segment Capital Expenditures ($M)
  • Segment Expense Structure, Operating Margins & Capital Allocation (ASU 2023-07) › BioPharma Systems — Segment Operating Income ($M) › BioPharma Systems — Segment Capital Expenditures ($M)
  • Non-GAAP Reconciliations, Net Leverage, Inventory Stages & Asset Schedules › Adjusted Net Income from Continuing Operations — Non-GAAP ($M) › Adjusted Diluted EPS from Continuing Operations — Non-GAAP ($) › Adjusted Diluted EPS Reported Growth YoY (%)
  • Non-GAAP Reconciliations, Net Leverage, Inventory Stages & Asset Schedules › Adjusted Net Income from Continuing Operations — Non-GAAP ($M) › Adjusted Diluted EPS from Continuing Operations — Non-GAAP ($) › Adjusted Diluted EPS FX-Neutral Growth YoY (%)
  • Product Remediation, Mass Tort Litigation Reserves & Regulatory Quality Inspections › Product Liability & Legal Matters Accrual Reserve Balance ($M) › Product Remediation Cost Estimate Adjustment Charge ($M)
  • Spun-Off Biosciences & Diagnostic Solutions (BDS Business) & Legacy Divested Units › BDS Business (SpinCo Standalone) — Total Revenues ($M) › BDS Business — Placed Instruments at Customer Sites, Net ($M) › BDS Business — RPO: Service & Equipment Installations ($M)
  • Spun-Off Biosciences & Diagnostic Solutions (BDS Business) & Legacy Divested Units › BDS Business (SpinCo Standalone) — Total Revenues ($M) › BDS Business — Placed Instruments at Customer Sites, Net ($M) › BDS Business — RPO: Minimum Consumable Commitments ($M)
  • Spun-Off Biosciences & Diagnostic Solutions (BDS Business) & Legacy Divested Units › BDS Business (SpinCo Standalone) — Total Revenues ($M) › BDS Business — Placed Instruments at Customer Sites, Net ($M) › BDS Business — Customer Contract Liabilities ($M)
  • Spun-Off Biosciences & Diagnostic Solutions (BDS Business) & Legacy Divested Units › Discontinued Operations (BDS Spin-Off) — Revenues Reported by BD ($M) › Discontinued Operations (BDS) — Income Before Income Taxes ($M)
  • Spun-Off Biosciences & Diagnostic Solutions (BDS Business) & Legacy Divested Units › Discontinued Operations (BDS Spin-Off) — Revenues Reported by BD ($M)
  • Manufacturing Footprint, Global Workforce, 3TG Supply Chain & Environmental Stewardship › Global Employees Headcount (associates) › U.S. Employees Headcount (associates)
  • Manufacturing Footprint, Global Workforce, 3TG Supply Chain & Environmental Stewardship › Eligible 3TG Conflict Mineral Smelters & Refiners in Supply Chain — Total (count) › Gold Refiners Identified in Supply Chain (count) › RMAP-Conformant Gold Refiners (count)
  • Manufacturing Footprint, Global Workforce, 3TG Supply Chain & Environmental Stewardship › Eligible 3TG Conflict Mineral Smelters & Refiners in Supply Chain — Total (count) › Tungsten Smelters Identified in Supply Chain (count) › RMAP-Conformant Tungsten Smelters (count)
  • Manufacturing Footprint, Global Workforce, 3TG Supply Chain & Environmental Stewardship › Eligible 3TG Conflict Mineral Smelters & Refiners in Supply Chain — Total (count) › Tantalum Smelters Identified in Supply Chain (count) › RMAP-Conformant Tantalum Smelters (count)

Dữ liệu cập nhật 2026-11-07.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Becton Dickinson

See a number that looks wrong?